KB-0742 dihydrochloride - ≥99% , CAS No.2416874-75-2

CAS: 2416874-75-2 Cat. No.: K649087 Molecular Weight: 360.33 PubChem CID: 155819527

GRADE & PURITY ≥99%

Storage

Store at 2-8°C,Desiccated

Shipped In

Wet ice

Overview

KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC 50 of 6 nM for CDK9/cyclin T1 . KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity

In Vitro

KB-0742 (6 hours; 0.1-10 μM; 22Rv1 cells) treatment significant reduction of downstream phosphorylation of RNA Pol II at Ser2 and Ser7, and diminished phosphorylation at Ser5. Global androgen receptor (AR)-FL and AR-V protein levels are significantly reduced starting at 6 h treatment time, which is accompanied by the reduction of phospho-AR levels (Ser81). KB-0742 (48-72 hours) treatment shows cytostatic effects in prostate cancer and leukemia cell lines. KB-0742 shows antiproliferative activity with GR 50 s of 0.183 μM and 0.288 μM for 22Rv1 cells and MV-4-11 AML cells, respectively. In 22Rv1 cells, KB-0742 rapidly downregulates nascent transcription, preferentially depleting short half-life transcripts and AR-driven oncogenic programs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 22Rv1 cells Concentration: 0.1 μM, 0.5 μM, 1 μM, 10 μM Incubation Time: 6 hours Result: Significant reduction of downstream phosphorylation of RNA Pol II at Ser2 and Ser7, and diminished phosphorylation at Ser5.

In Vivo

KB-0742 (3-30 mg/kg; p.o.; daily; over 21 days) is well tolerated even at high dose, while significantly reducing tumor burden in 22Rv1 human prostate cancer cell line-derived xenograft (CDX) models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male CB17-SCID mice injected with 22Rv1 human prostate cancer cells Dosage: 3 mg/kg, 10 mg/kg, and 30 mg/kg Administration: p.o.; daily; over 21 days Result: Significantly reduced tumor growth in castration-resistant prostate cancer (CRPC).

Form:Solid

IC50& Target:CDK9/cyclinT1 6 nM (IC 50 )

Specifications

Specifications & Purity

≥99%

Biochemical and Physiological Mechanisms

KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC 50 of 6 nM for CDK9/cyclin T1 . KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride ha

Storage

Store at 2-8°C, Desiccated

Shipped In

Wet ice

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Purity

≥99%

Names and Identifiers

• Canonical Smiles: CCC(CC)C1=NC2=CC=NN2C(=C1)NC3CCC(C3)N.Cl.Cl
• IUPAC Name: (1S,3S)-3-N-(5-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine;dihydrochloride
• InChIKey: OTUPXOLLHVLWQF-NJHZPMQHSA-N
• INCHI: 1S/C16H25N5.2ClH/c1-3-11(4-2)14-10-16(19-13-6-5-12(17)9-13)21-15(20-14)7-8-18-21;;/h7-8,10-13,19H,3-6,9,17H2,1-2H3;2*1H/t12-,13-;;/m0../s1
• PubChem CID: 155819527
• Molecular Weight: 360.33

Chemical and Physical Properties

• Solubility: H2O : 100 mg/mL (277.52 mM; Need ultrasonic) DMSO : 62.5 mg/mL (173.45 mM; Need ultrasonic)